Phase I study of gemcitabine using a once every 2 weeks schedule
1997

Phase I Study of Gemcitabine Every Two Weeks

Sample size: 52 publication Evidence: moderate

Author Information

Author(s): JB Vermorken, JP Guastalla, SR Hatty, DE Seitz, B Tanis, C McDaniels, MD Clavel

Primary Institution: University Hospital 'Vrije Universiteit', Amsterdam, Netherlands

Hypothesis

To determine the maximum tolerated dose (MTD) of gemcitabine using a once every 2 weeks schedule.

Conclusion

The study concluded that the once every 2 weeks schedule is not the most appropriate dosing schedule for gemcitabine, but it demonstrates a safety profile allowing for doses significantly higher than previously recommended.

Supporting Evidence

  • The maximum tolerated dose (MTD) for the once every 2 weeks schedule was found to be 5700 mg m-2.
  • Neutropenia was identified as the dose-limiting toxicity.
  • One minor response was observed in a heavily pretreated breast cancer patient.

Takeaway

Doctors tested a new way to give a cancer medicine called gemcitabine to see how much they could safely give every two weeks. They found that patients could handle much higher doses than before.

Methodology

This was a phase I, dose-ranging, open-label, non-randomized study where gemcitabine was given as a 30-min infusion once every 2 weeks.

Limitations

The study was limited by the small sample size and the specific patient population with advanced refractory solid tumors.

Participant Demographics

52 patients (22 male, 30 female) aged 18-75 with advanced refractory solid tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication